Inhibition of PRMT1 Mediated FLT3 Arginine Methylation As a Potent Therapeutic Strategy for MLL-r ALL
Zhu Y, He X, Dong H, Sun J, Wang H, Zhang L, Miao Y, Jin J, Shen Y, Chen J, Muschen M, Chen C, Konopleva M, Sun W, Zhang B, Kuo Y, Carlesso N, Marcucci G, Li L. Inhibition of PRMT1 Mediated FLT3 Arginine Methylation As a Potent Therapeutic Strategy for MLL-r ALL. Blood 2018, 132: 892. DOI: 10.1182/blood-2018-99-115139.Peer-Reviewed Original ResearchFms-like receptor tyrosine kinase 3Primary MLLTyrosine kinase inhibitorsNSGS miceFLT3 phosphorylationCombination treatmentFLT3 tyrosine kinase inhibitorsPKC412 treatment